Ehrlich Adam C, Patel Shyam, Meillier Andrew, Rothstein Robin D, Friedenberg Frank K
a Section of Gastroenterology , Lewis Katz School of Medicine at Temple University , Philadelphia , PA 19140 , USA.
b Department of Medicine , Lewis Katz School of Medicine at Temple University , Philadelphia , PA 19140 , USA.
Expert Rev Anticancer Ther. 2017 Mar;17(3):247-255. doi: 10.1080/14737140.2017.1283987. Epub 2017 Feb 1.
Patients with inflammatory bowel disease are at an increased risk of colorectal cancer when compared to the general population. Chronic inflammation is thought to be the underlying cause, and medications that reduce inflammation have the potential to reduce the risk of colorectal cancer. Areas covered: After conducting a PubMed search for relevant literature, we examined several classes of medications that have been studied as potential chemopreventive agents. These include 5-aminosalicylates, thiopurines, tumor necrosis factor antagonists, ursodeoxycholic acid, NSAIDs, and statins. Expert commentary: While each class of medications has some data to support its use in chemoprevention, the majority of the evidence in each case argues against the routine use of these medications solely for a chemopreventive benefit.
与普通人群相比，炎症性肠病患者患结直肠癌的风险增加。慢性炎症被认为是潜在病因，而减轻炎症的药物有可能降低患结直肠癌的风险。涵盖领域：在对PubMed上的相关文献进行检索后，我们研究了几类已被作为潜在化学预防剂进行研究的药物。这些药物包括5-氨基水杨酸类、硫唑嘌呤、肿瘤坏死因子拮抗剂、熊去氧胆酸、非甾体抗炎药和他汀类药物。专家评论：虽然每类药物都有一些数据支持其在化学预防中的应用，但在每种情况下，大多数证据都反对仅为了化学预防益处而常规使用这些药物。
